Evidence map›Paper›PMID 28251496›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.

M Cuadros, V Sánchez-Martín, A Herrera, C Baliñas, J Martín-Padrón, L Boyero, P Peinado, P P Medina

RetractedErratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. The SMARCA4NPJ precision oncology · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. The Role of BRG1 in Antioxidant and Redox Signaling.Oxidative medicine and cellular longevity · 2020
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M CuadrosDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
V Sánchez-MartínDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.ORCID http://orcid.org/0000-0003-1501-6681
A HerreraGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
C BaliñasGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
J Martín-PadrónDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
L BoyeroDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
P PeinadoGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
P P MedinaGENYO, Centre for Genomics and Oncological Research, Granada, Spain. pedromedina@ugr.es.
Universidad de Granada · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction/purposeBRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated. MATERIALS AND

methodsWe assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay.

resultsBRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt's lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line.

conclusionOur study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticDNA HelicasesHumansLeukemiaLymphomaMicroRNAsNuclear ProteinsTranscription FactorsTumor Cells, CulturedDNA HelicasesMicroRNAsMIRN155 microRNA, humanNuclear ProteinsSMARCA4 protein, humanTranscription FactorsBRG1LeukemiamiR-155Prednisolone

Identifiers

PMID28251496
OpenAlexW2592670217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.